Objectives. We aimed to evaluate a novel clinical program designed to address unsafe use of opioids prescribed for pain-the Opioid Reassessment Clinic (ORC)-to inform practice and health system improvement. Design. Controlled, retrospective cohort study. Setting. The ORC is a multidisciplinary clinic in a primary care setting in a Veterans Health Administration hospital designed to perform longitudinal treatment of patients with unsafe use of opioids prescribed for pain, including tapering or rotating to the partial opioid agonist buprenorphine. Subjects. We included patients referred to the ORC from March 1, 2016, to March 1, 2017, who had an intake appointment (intervention group) and who did not (control group). Methods. We compared a priori-defined metrics at the patient, clinic process, and health system levels and compared metrics between groups. Results. During the study period, 114 veterans were referred to the ORC, and 71 (62%) of these had an intake appointment. Those in the intervention group were more likely to trial buprenorphine (N ¼ 41, 62% vs N ¼ 1, 2%, P < 0.01) and had greater reductions in their full agonist morphine equivalent daily dose than those in the control group (30 mg [interquartile range {IQR} ¼ 0-120] vs 0 mg [IQR ¼ 0-20] decrease, P < 0.01). Of those engaging in the ORC, 20 (30%) had not transitioned chronic pain management back to their primary care providers (PCPs) by the end of follow-up. Only one patient transitioned the management of buprenorphine to the PCP. Conclusions. Results suggest the ORC was effective in reducing total prescribed opioid doses and in transitioning patients to partial-agonist therapy, but PCP adoption strategies are needed.
Introduction
More than one in 10 adults in the United States report chronic pain [1] , and a high proportion of primary care visits involve the management of chronic pain [2] . Primary care providers (PCPs) frequently prescribe fullagonist opioids for treatment of chronic pain despite safety concerns and minimal evidence for efficacy [3] [4] [5] .
Safety concerns surrounding opioid therapy are increasing and include opioid use disorder (OUD) [6] and overdose [7, 8] . As a result, the Centers for Disease Control and Prevention released a guideline for "Prescribing Opioids for Chronic Pain" that emphasizes safe prescribing and the use of multimodal approaches to chronic pain management [9] . The Surgeon General [10] , Food 2018 American Academy of Pain Medicine. This work is written by US Government employees and is in the public domain in the US.
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However, recent data describing the prevalence of prescription opioid use and misuse, as well as the prevalence of OUD, suggest that balancing the potential benefits of pain relief from opioids with their adverse effects remains a challenge for patients, providers, and health systems [14] . This challenge is especially felt among US veterans, for whom opioid overdoses occur at approximately twice the rate compared with nonveterans [15] . Although the strongest evidence to date demonstrate no added benefit of long-term opioid treatment (LTOT) in veterans with chronic pain [5] , and despite veterans' demonstrated ambivalence about the benefit and safety of LTOT [16] , veterans are still commonly prescribed LTOT [17] . Optimal strategies for modification, dose reduction, or discontinuation of LTOT are unclear [18] .
In 2011, the VA Connecticut Healthcare System (VACHS) established a multidimensional performance improvement strategy to improve the quality of chronic pain management [19] . As part of this strategy, a team of clinicians, administrators, and quality improvement specialists designed the Opioid Reassessment Clinic (ORC). The ORC is a multidisciplinary care team staffed by an internist, addiction psychiatrist, advanced practice nurse (APRN), nurse case manager and health psychologist. It is designed to offer team-based assessment and longitudinal, multimodal treatment of pain in patients prescribed opioid regimens deemed unsafe by their PCPs [20] . Treatments that involve medications (structured opioid prescribing and nonopioid prescribing), behavioral interventions (cognitive behavioral therapy for pain), and other modalities (e.g., acupuncture, chiropractic, and yoga) are encouraged and coordinated in the clinic through on-site offerings and facilitated referrals. Because of safety concerns associated with concurrent use of marijuana and full-agonist opioids [21] , as well as concurrent use of benzodiazepines and full-agonist opioids [22, 23] , efforts are made to encourage patientcentered decreases or abstinence from these substances when possible.
One pharmacotherapeutic strategy employed by the ORC for safer prescribing of opioids in the treatment of chronic pain is the offer of transitioning from a fullagonist opioid to a partial m opioid receptor agonist, buprenorphine. Buprenorphine has been shown to impact pain intensity in patients with both chronic pain and OUD [24] , and both transdermal and buccal formulations have demonstrated effectiveness in managing chronic pain [25, 26] . Given buprenorphine's pharmacologic properties-specifically a ceiling effect for respiratory depression [27, 28] -it is considered safer than fullagonist opioids in terms of overdose risk. As such, it is designated a schedule III controlled substance, in contrast to most full-agonist opioids in schedule II (higher risk), including commonly prescribed medications like oxycodone and hydrocodone. Physicians and the APRN in the ORC are certified to prescribe buprenorphine/naloxone, allowing for transition to buprenorphine/naloxone therapy without referral to substance use disorder treatment settings.
Clinical Processes
Eligibility for buprenorphine among patients referred to the ORC depends on comorbid OUD, characteristics of LTOT regimens, and other historical features. During initial assessment, patients are assessed for OUD. If they are diagnosed with OUD, they are presented with the option of transitioning to one of two opioid agonist treatments: methadone or buprenorphine. While patients may receive buprenorphine in the ORC, if the patient requires more structured support than the ORC can provide or if the patient opts for methadone therapy, the patient is referred via warm handoff to specialty addiction treatment settings at the same Depatment of Veterans Affairs (VA) facility. Patients who do not have OUD but demonstrate physiologic opioid dependence where the benefits of LTOT do not outweigh the harms are offered a choice: slow opioid taper or fast taper and rotation to buprenorphine. We strive to express empathy and a reassurance to the patient about nonabandonment. Patient preference is the main driver determining next steps; however, patients with very high opioid doses (e.g., >400 mg morphine equivalent daily dose [MEDD]), those who are coprescribed benzodiazepines or other sedatives, and those who are already experiencing opioid-related harms (e.g., oversedation) are counseled that changes to their regimen need to start immediately.
Buprenorphine doses generally start at 4-8 mg sublingually per day, can be titrated up, and may be split into twice or thrice daily dosing if patients prefer. For patients who choose to taper, ORC providers partner with patients and share in the responsibility of maintaining a flexible taper with a pace determined with patients' input; generally tapers start at a reduction of 5% in total daily dose per two-or four-week interval. For all patients prescribed opioids in the ORC, we check prescription drug monitoring program reports every three months or more frequently, and we obtain urine drug toxicology screens in the clinic every six months or more frequently. Although in general ORC providers do not take over benzodiazepine prescribing, we encourage patients prescribed both opioids and benzodiazepines to taper the benzodiazepine(s) and collaborate with the prescriber of the benzodiazepine(s) to coordinate. We encourage those on opioids and marijuana to decrease or discontinue their marijuana use.
To inform strategies for improved engagement in treatment options offered by the ORC, including offering buprenorphine, as well as to describe the process and clinical outcomes of veterans who transition from full agonist opioids to buprenorphine, we conducted a controlled quality improvement study of veterans referred to the ORC between March 1, 2016, and March 1, 2017, the time period immediately following release of the CDC guideline and after buprenorphine was placed on VA Connecticut's preferred formulary.
Methods
We performed a retrospective cohort study that was Health Insurance Portability and Accountability Act of 1996 compliant and determined to be quality improvement/not human subjects research by the Human Subjects Subcommittee of the VACHS' Institutional Review Board. Using data collected on referrals to the ORC over a one-year period (March 1, 2016-March 1, 2017), we systematically evaluated the ORC using a priori-defined metrics at the patient, clinic process, and health system levels. Our study involved a concurrent control group to increase validity and minimize bias due to temporal trends [29] .
Patient Selection
Eligible for this study were veterans for whom a referral had been placed to the ORC on or between March 1, 2016, and March 1, 2017. We excluded patients 1) if they were being treated for OUD with buprenorphine or methadone at the time of referral, as these patients were typically redirected toward substance use disorder treatment clinics for ongoing opioid agonist therapy for OUD, or 2) if they died during the follow-up period. For included patients, we searched the electronic medical record (EMR) to determine if those referred attended an intake appointment at the ORC during the follow-up period; those who did not (because they declined to schedule an appointment or did not attend their scheduled appointment) were designated the control group.
Measures
With respect to patient-level measures, we assessed demographic characteristics, medical and mental health comorbidities, and whether the referral was placed from the VA facility where the ORC is located (West Haven, CT, USA) or from another VA facility within VACHS. Patient-level process outcomes included engagement in various pain treatments offered by the ORC. Patientlevel clinical outcomes included change in MEDD (computed using a standardized conversion calculator) from the time of referral to the final visit in the ORC, concurrent benzodiazepine prescriptions, concurrent marijuana use, choice of a slow taper, and choice of a trial on buprenorphine.
The ORC is located at the main inpatient/outpatient facility of VA Connecticut Healthcare System (West Haven, CT, USA); other VA sites in Connecticut include a second, large outpatient facility 40 miles away, as well as six community-based outpatient clinics. We assumed that the location where the referral was placed was the location where patients receive primary care and differentiated between patients whose primary care occurred at West Haven vs at other sites to determine the impact of traveling to a new facility on a patient's ability to attend the ORC. We calculated MEDD for full-agonist opioids only because of the difference in safety profile between full-agonist and partial-agonist opioids. Other treatments that we measured included those offered onsite by ORC staff (health psychology for pain, yoga), and those that involve facilitated referrals (acupuncture, chiropractic, ketamine infusion, physical therapy, occupational therapy, or aquatherapy). Because all new patients in the ORC are offered intake appointments with a health psychologist in the clinic, we defined health psychology treatment engagement as two completed appointments with a health psychologist. For all other treatments mentioned above, engagement was defined as having had one identifying visit.
With respect to clinic process measures, we measured the time between referral placement and the initial appointment, as well as length of stay in the clinic. We followed the intervention group from the time of referral through January 1, 2018, noting patients still receiving treatment from the ORC at the end of the follow-up period. For those who had transitioned back to their primary care provider during this period, we considered their length-of-stay in the ORC to be the number of days between their first and last ORC appointments. To determine an appropriate time period over which to follow the control group, we calculated the mean length of stay of the intervention group and followed the control group for this length of time.
At the health system level, we assessed the extent to which VACHS primary care providers could take over the care plans initiated by the ORC by measuring the proportion of veterans whose pain care was transitioned back to a PCP (in the context of a planned transition or because the patient chose not to return to the ORC, in which cases care returned to the PCP by default). We also determined who was successfully transitioned to a PCP among those who initiated buprenorphine in the ORC.
Statistical Analyses
We performed descriptive statistics and compared the intervention and control groups. We used t tests for continuous variables or a nonparametric counterpart for nonnormally distributed continuous variables, and chi-square for categorical variables to compare characteristics between the intervention and control group, considering P < 0.05 to be statistically significant. We calculated the difference in full-agonist MEDD between the time of referral and reengagement with primary care in the intervention group and compared this with the change in full-agonist MEDD from referral to the end of follow-up for the control group using a Mann-Whitney U test. We compared benzodiazepine prescribing (yes/no) and marijuana use (presence/absence of cannabinoids on urine toxicology) during the follow-up period for the intervention and control groups using chisquare. We performed statistical analyses using STATA, version 14.1 (StataCorp LLC, College Station, TX, USA).
Results
From March 1, 2016, through March 1, 2017, 114 veterans were referred to the ORC. Of these, 71 (62%) successfully had an appointment in the ORC during the follow-up period (March 1, 2016, through January 1, 2018), and 43 (38%) did not. We excluded from our analyses nine veterans who were already on opioid agonist therapy for OUD (who were redirected to substance use disorder clinics, N ¼ 7) or who died during the follow-up period (N ¼ 2). Our final analytic sample included 66 veterans in the intervention group and 39 in the control group. The two groups had similar age distributions, were primarily male, identified primarily as white, most commonly were referred from the same VA facility where the ORC is located, and had similar medical, mental health, and substance-related comorbidities.
They were prescribed daily doses of opioids at doses greater than 60 mg MEDD, most commonly identified their primary pain site as their back, and were prescribed benzodiazepines and used marijuana at similar rates ( Table 1) .
The median length of time between referral and intake appointment in the ORC (interquartile range [IQR] 23-65.) was 45 (23-65) days for the intervention group (Table 2) . Among this group, 46 (70%) ceased their care in the ORC and reengaged with their primary care providers during the follow-up period; 20 (30%) veterans were receiving ongoing care in the ORC at the end of follow-up. Veterans who engaged in the ORC were significantly more likely to engage in health psychology for pain (N ¼ 15, 23%) than those who did not engage (N ¼ 1, 3%, P ¼ 0.01). More veterans who engaged in the ORC trialed acupuncture, aquatherapy, chiropractic treatment, and yoga than did those not engaging, but these differences did not achieve statistical significance.
Veterans who engaged in the ORC were significantly more likely to opt for a slow taper (N ¼ 24, 37%) than those who did not engage (N ¼ 1, 3%, P < 0.01). They were also significantly more likely to trial partial agonist therapy (N ¼ 41, 62%) than those who did not engage (N ¼ 1, 2%, P < 0.01). Among the partial agonist formulations, buprenorphine/naloxone was most commonly used (N ¼ 40, 98%, in the intervention group; N ¼ 1, 100%, in the control group). Buprenorphine tablets without co-formulated naloxone were trialed in two (5%) veterans in the intervention group, and buprenorphine transdermal patch was used in one (2%) veteran in the intervention group. One veteran (2%) in the intervention group who transitioned to a partial agonist (buprenorphine transdermal patches) successfully transitioned to primary care prescribing; all others who received ongoing partial agonist therapy remained engaged in care in the ORC.
The intervention group demonstrated a median (IQR) decrease of 30 (0-120) mg MEDD, and this was a significantly greater decrease than the control group, for whom no decrease was detected (0 mg change, IQR ¼ 0-20 mg increase, P < 0.01; Table 3 ). No difference was detected in the change in benzodiazepine prescriptions for the intervention group (at referral, N ¼ 20, 30%; at reengagement, N ¼ 19, 29%) compared with the control group (at referral, N ¼ 11, 28%; at the end of follow-up, N ¼ 11, 28%). Similarly, no difference was detected in the change in cannabinoid use for the intervention group (at referral, N ¼ 10, 15%; at reengagement, also N ¼ 10, 15%) compared with the control group (at referral, N ¼ 5, 13%; at reengagement, N ¼ 4, 11%).
Changes in MEDD in the intervention group demonstrated durability for up to three months after reengagement with PCPs. Among those returning to PCP-directed opioid therapy, no significant difference was detected in the median or distribution of the MEDD at the time of reengagement with PCPs (median ¼ 60 mg, IQR ¼ 0-138 mg) and three months thereafter (median ¼ 45 mg, IQR ¼ 0-125 mg, P ¼ 0.14), although the median MEDD did continue to decrease.
Discussion
We have demonstrated in a controlled quality improvement study that a novel clinical program designed to improve the assessment and treatment of unsafe opioid use within primary care can engage patients with high-risk opioid use in multiple modalities of pain treatment, including rotating from full agonist to the partial agonist buprenorphine. Veterans referred to the ORC demonstrated significant decreases in their overall dose of full agonist opioids when compared with a similar group of veterans with high-risk opioid use who did not engage in the ORC, and these dose changes were maintained for at least three months after these patients' primary care providers resumed management of their chronic pain. Nearly two-thirds (62%) of those who engaged in the ORC rotated to buprenorphine, which has an improved safety profile compared with full-agonist opioids [27, 28] .
We did not detect a statistically significant difference in the change in the proportion of patients co-prescribed benzodiazepines or who concurrently used marijuana during treatment in the ORC when compared with a similar group of patients at high risk. This is likely explained by the following: while the ORC assumed opioid prescribing, we did not take over benzodiazepine prescribing; thus changes in benzodiazepine prescribing were less often achieved. While patients referred to the ORC successfully engaged in multiple modalities of pain treatment both within the clinic and via facilitated referrals, only engagement with health psychology for pain was significantly more likely for those in the intervention group, likely because a health psychologist is embedded in the ORC and referral to this provider was a part of most ORC patients' treatment plans.
Our results suggest multiple opportunities for practice improvement. Of all veterans referred to the ORC during our study period, 38% did not successfully have an intake appointment, representing a potential gap in care for patients at risk for adverse outcomes from LTOT. Our study did not capture predictors of successful intake in the clinic, but these may involve issues of access to care and transportation, referring providers' evolving understanding of patients' candidacy for the ORC, stigma surrounding the clinic or OUD and chronic pain, or patients' choice to have their pain be managed by their PCP instead of by a specialty clinic. These factors may have impacted the median time between referral and intake appointment (45 days), which reflects issues of access as well as patients missing and/or rescheduling their intake appointments. Qualitative data suggest that the patient experience may influence veterans' attitudes toward tapering LTOT. For example, veterans may be more likely to taper if they perceive that they are supported in doing so, if they perceive that communication between themselves and their providers is adequate, and if care is not fragmented [30] . Veterans may also be more open to tapering if they are assured that the health system is not abandoning them [31] . Therefore, ongoing education about the ORC's potential benefit to patients should be offered to PCPs, and communication between ORC staff and PCPs should be optimized to reduce these barriers to veterans.
Consistent strategies to address co-occurring substance use such as benzodiazepines and marijuana are needed to guide the management of patients on LTOT also prescribed or using these substances. While VA clinical practice guidelines suggest tapering benzodiazepines in patients prescribed LTOT [12] , tapering requires caution and can be particularly difficult among veterans with post-traumatic stress disorder (PTSD), for whom tapering can be compounded by PTSD exacerbations. The Food and Drug Administration (FDA) has recently issued a statement that acknowledges that benzodiazepine prescriptions should not limit access to buprenorphine in selected patients [32] , and ORC prescribers may have been reluctant to enforce benzodiazepine tapers in patients already making reductions in their MEDD.
Our results also suggest opportunities for health system improvement. Many (N ¼ 20, 30%) veterans who engaged in the ORC did not transition their care back to their PCPs during our follow-up period, and, of 41 veterans in our study who trialed partial agonist therapy for pain, only for one was the management of this medication successfully transitioned to the primary care setting. These findings reflect broader trends in provider discomfort managing chronic pain that may involve tapering LTOT [33] , as well as limited access to buprenorphine in community and rural settings [34, 35] . Implementation interventions such as academic detailing that target outlying community-based outpatient clinics are one planned strategy to increase PCPs' awareness of and comfort with these topics, including training and certification of PCPs in the use of buprenorphine/ naloxone.
Our study has methodological limitations. The nonrandomized study design is subject to selection bias because our control group was generated post hoc and consisted of patients who did not engage in the ORC. The patients who did not engage may differ systematically from those who did with respect to challenges in engaging with the health care system or unmeasured vulnerabilities in this group. Important clinical outcomes such as patient-reported function, pain intensity, adverse events, and mortality are lacking. Patients' experience with buprenorphine was not characterized in detail. However, ORC philosophy embraces only voluntary engagement in ongoing buprenorphine treatment, so it is reasonable to assume that those who stayed on buprenorphine did so because they preferred it over full agonist therapy.
Coordinated efforts are needed to train and increase PCPs' awareness that they can manage patients with complex chronic pain once stabilized. Randomized trials of buprenorphine's role in assisting in dose reduction are also needed. One recently launched trial-the Veterans Pain Care Organizational Improvement Comparative Effectiveness (VOICE) trial-examines this question as well as its central question of the comparative effectiveness of a higher resource-intensive vs lower resourceintensive care management strategy for managing pain while lowering opioid dose. More definitive randomized controlled trial data about the role of buprenorphine in dose-lowering may help establish this as an FDAapproved indication for the use of buprenorphine. Currently, many VA sites consider this "off-label" use and will not allow buprenorphine prescribing without a diagnosis of OUD.
The ORC shows promise as an efficacious, multidisciplinary care model for improving the safety of LTOT for pain. Identified areas of improvement include greater PCP training in and adoption of evidence-based practices for managing LTOT, improved engagement with multimodal treatments offered by the ORC, and strategies for managing patients on LTOT who also use other substances such as benzodiazepines or marijuana. Future studies should more rigorously assess the role of buprenorphine in the management of chronic pain and test less resourceintensive models for the management of patients with high-risk LTOT.
